The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | DaraVd in the second-line for lenalidomide-refractory patients with myeloma
In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the use of daratumumab, bortezomib, and dexamethasone (DaraVd) in the second-line setting for patients with multiple myeloma (MM) who are refractory to lenalidomide. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
